कृपया अन्य खोज का प्रयास करें
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Francis V. Chisari | - | - | Scientific Advisor |
Vicki L. Sato | 75 | 2016 | Independent Chairman |
Phillip A. Sharp | 79 | 2017 | Independent Director |
George A. Scangos | 76 | 2017 | Director |
Thomas O. Daniel | 70 | 2017 | Scientific Advisor |
Jeffrey V. Ravetch | 73 | - | Scientific Advisor |
Robert J. Perez | 60 | 2017 | Independent Director |
Robert J. More | 56 | 2016 | Independent Director |
Jeffrey A. Bluestone | 70 | - | Scientific Advisor |
George H. Poste | 80 | - | Scientific Advisor |
Sona Saira Ramasastry | 48 | 2019 | Independent Director |
Jeffrey S. Hatfield | 66 | 2020 | Independent Director |
Emilio A. Emini | 71 | 2015 | Scientific Advisor |
Robert Taylor Nelsen | 62 | 2016 | Independent Director |
Charles Elliott Sigal | 72 | 2020 | Independent Director |
Janet Napolitano | 66 | 2020 | Independent Director |
Charles M. Rice | - | - | Scientific Advisor |
Susanna Naggie | - | - | Scientific Advisor |
Klaus Frueh | 64 | 2016 | Co-Founder & Scientific Advisor |
Louis J. Picker | - | - | Co-Founder & Scientific Advisor |
Lawrence Corey | 76 | 2016 | Co-Founder & Scientific Advisor |
Marianne De Backer | 55 | 2023 | CEO & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है